Catalent | CTLT - Cash And Equivalent


Catalent reported $335M in Cash and Equivalent for its fiscal quarter ending in September of 2024.



Cash And Equivalent Change Date
Agilent USD 1.79B 254M Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Bruker USD 293.1M 201.1M Sep/2025
Centene USD 17.89B 830M Dec/2025
Charles River Laboratories USD 207.1M 24.27M Sep/2025
Cigna USD 6.02B 1.7B Sep/2025
Danaher USD 4.62B 3.09B Dec/2025
Dentsply International USD 363M 4M Sep/2025
Elevance Health USD 9.49B 778M Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Hologic USD 2.17B 208.5M Dec/2025
Humana USD 4.2B 1.19B Dec/2025
Illumina USD 1.42B 368M Dec/2025
Intuitive Surgical USD 9.03B 601.6M Dec/2025
IQVIA Holdings USD 1.98B 166M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Laboratory Of America USD 598.1M 49.2M Sep/2025
Lonza CHF 1.11B 286M Dec/2024
McKesson USD 2.96B 1.05B Dec/2025
Merck EUR 1.17B 161M Jun/2025
Merck USD 18.17B 10.16B Sep/2025
Mettler Toledo International USD 69.06M 7.24M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Quest Diagnostics USD 420M 12M Dec/2025
Repligen USD 748.75M 39.89M Sep/2025
Revvity USD 919.86M 11.53M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
UnitedHealth USD 28.12B 2.49B Dec/2025
Waters USD 587.83M 128.71M Dec/2025
West Pharmaceutical Services USD 791.3M 162.8M Dec/2025